SCHEMBL4625484

SCHEMBL4625484

CC(N)(Cc1ccc2nc(-c3ccccc3)ccc2c1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.50
ALDH1A1 P00352 4/20 0.50
BLM P54132 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
HPGD P15428 3/20 0.50
HSD17B10 Q99714 3/20 0.50
CYP3A4 P08684 2/20 0.50
MAPT P10636 2/20 0.50
PMP22 Q01453 2/20 0.50
GAA P10253 2/20 0.50
USP2 O75604 1/20 0.50
EGFR P00533 1/20 0.50
CYP1A2 P05177 1/20 0.50
FYN P06241 1/20 0.50
POLB P06746 1/20 0.50
ALOX15 P16050 1/20 0.50
APEX1 P27695 1/20 0.50
ADRA1A P35348 1/20 0.50
PTGS2 P35354 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4750015 0.83 ITGB1 (0.53) KDM4EALDH1A1BLMMEN1KMT2A
SCHEMBL4626504 0.83 ITGB1 (0.53) KDM4EALDH1A1BLMMEN1KMT2A
SCHEMBL20809063 0.83 PSMB5 (0.44) KDM4EALDH1A1BLMMEN1KMT2A
SCHEMBL29982408 0.80 CYP1A2 (0.62) KDM4EALDH1A1BLMMEN1KMT2A
SCHEMBL8939501 0.80 CYP1A2 (0.62) KDM4EALDH1A1BLMMEN1KMT2A
SCHEMBL20809049 0.78 MAOA (0.40) KDM4EALDH1A1BLMMEN1KMT2A
SCHEMBL29746236 0.77 KDM4E (0.56) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL11816557 0.77 KDM4E (0.56) KDM4EALDH1A1MEN1KMT2AHPGD
Methane SCHEMBL11817095 0.76 KDM4E (0.55) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL31038113 0.75 CYP1A2 (0.52) KDM4EALDH1A1MEN1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501801-B1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES UCB PHARMA SA (BE) 2008-01-23 EP disclosed